Get started
Author

Yasutoshi Nozaki

ORCID: 0009-0006-1771-5557
Observed ORCID: 0009-0006-1771-5557
OpenAlex ID: A5109932723
Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice
2016 · Satoshi Tanaka, Hayato Hikita, et al. · Hepatology · 391
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy
2022 · Yuta Myojin, Takahiro Kodama, et al. · Cancers · 88
PDF
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy
2022 · Takayuki Matsumae, Takahiro Kodama, et al. · Cancers · 77
PDF
DNase II activated by the mitochondrial apoptotic pathway regulates RIP1-dependent non-apoptotic hepatocyte death via the TLR9/IFN-β signaling pathway
2018 · Yoshinobu Saito, Hayato Hikita, et al. · Cell Death and Differentiation · 67
PDF
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
2022 · Kazuki Maesaka, Ryotaro Sakamori, et al. · Hepatology Research · 57
Development of a novel Borna disease virus reverse genetics system using RNA polymerase II promoter and SV40 nuclear import signal
2006 · Hideyuki Yanai, Yohei Hayashi, et al. · Microbes and Infection · 47
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
2023 · Kazuki Maesaka, Ryotaro Sakamori, et al. · PLoS ONE · 29
PDF
Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels
2020 · Katsuhiko Sato, Hayato Hikita, et al. · PLoS ONE · 29
PDF
Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
2015 · Hayato Hikita, Takahiro Kodama, et al. · Cancer Prevention Research · 29
Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver
2016 · Tasuku Nakabori, Hayato Hikita, et al. · Scientific Reports · 25
PDF
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis
2022 · Yuki Tahata, Ryotaro Sakamori, et al. · Hepatology Research · 22
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
2024 · Machiko Kai, Hayato Hikita, et al. · PLoS ONE · 17
PDF
Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis
2022 · Yuki Tahata, Ryotaro Sakamori, et al. · Hepatology Research · 13
The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs
2025 · Kazuhiro Murai, Hayato Hikita, et al. · Hepatology Research · 11
PDF
Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus
2023 · Yuki Tahata, Hayato Hikita, et al. · Journal of Gastroenterology · 11
PDF
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral
2023 · Takayuki Matsumae, Takahiro Kodama, et al. · Cancers · 11
PDF
Persistent hepatocyte apoptosis promotes tumorigenesis from diethylnitrosamine-transformed hepatocytes through increased oxidative stress, independent of compensatory liver regeneration
2021 · Yasutoshi Nozaki, Hayato Hikita, et al. · Scientific Reports · 11
PDF
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis
2022 · Kumiko Shirai, Hayato Hikita, et al. · PLoS ONE · 8
PDF
NRF2–COX2–PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma
2026 · Shuhei Yamamoto, Takahiro Kodama, et al. · Hepatology · 7
Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals
2024 · Takayuki Iwamoto, Yasutoshi Nozaki, et al. · Journal of Gastroenterology · 7
PDF
Factors involved in gastroesophageal varix‐related events in patients with hepatitis C virus‐related compensated and decompensated cirrhosis after direct‐acting antiviral therapy
2024 · Yuki Tahata, Hayato Hikita, et al. · Hepatology Research · 6
PDF
Gab1 in livers with persistent hepatocyte apoptosis has an antiapoptotic effect and reduces chronic liver injury, fibrosis, and tumorigenesis
2021 · Naoki Mizutani, Hayato Hikita, et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 6
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma
2025 · Kazuki Maesaka, Hayato Hikita, et al. · Journal of Gastroenterology · 4
PDF
Prognostic impact of worsening of esophageal varices after balloon‐occluded retrograde transvenous obliteration
2022 · Kazuma Shinkai, Ryotaro Sakamori, et al. · Journal of Gastroenterology and Hepatology · 4
PDF
Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma
2026 · Akira Nishio, Takahiro Kodama, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Works count: 51
Citation count: 1,000
H-index: 13
I10-index: 17
Year
Topic
Type